This study was an open-label, multicentre, non-randomised study to investigate the safety, tolerability, PK and preliminary anti-tumour activity of the anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with the anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumours. Here, PDCD1 is linked to neoplasm.